Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.

Iqbal, Muhammad Shahid; Shaikh, Ghazia; Chatterjee, Sanjoy; Cocks, Helen; Kovarik, Josef

Iqbal, Muhammad Shahid; Shaikh, Ghazia; Chatterjee, Sanjoy; Cocks, Helen; Kovarik, Josef.

Afiliación

Iqbal MS; Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.
Shaikh G; Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.
Chatterjee S; Department of Oncology, Tata Medical Centre, Kolkata 700 156, India.
Cocks H; Department of Otolaryngology, Sunderland Royal Hospital, Kayll Road, Sunderland SR4 7TP, UK.
Kovarik J; Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.

Case Rep Oncol Med ; 2014: 162534, 2014.

Article en En | MEDLINE | ID: mdl-25136467

RESUMEN

Salivary ductal carcinomas (SDCs) are extremely rare and aggressive malignancies, accounting for approximately 6% of all salivary gland malignancies. One distinct feature is their resemblance to ductal carcinomas of breast. A significant percentage of SDCs overexpress Her2 and the use of targeted therapy with trastuzumab can be considered in these patients. We report a rare case of long term disease control with trastuzumab in Her2 positive metastatic parotid ductal carcinoma. Our case also highlights that isolated brain metastasis should be managed aggressively to allow optimal local control when systemic disease is under remission with trastuzumab. We have also reviewed the published literature on the use of trastuzumab in SDCs.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Oncol Med Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google